Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5075-5075 ◽  
Author(s):  
Michael J. Morris ◽  
Yohann Loriot ◽  
Christopher Sweeney ◽  
Karim Fizazi ◽  
Charles J. Ryan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Bone Metastases ◽  
Randomized Trial ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Radium 223

scholarly journals Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate ◽  
2019 ◽  
Vol 79 (14) ◽  
pp. 1683-1691 ◽  
Author(s):  
Oliver Sartor ◽  
Daniel Heinrich ◽  
Neil Mariados ◽  
Maria José Méndez Vidal ◽  
Daniel Keizman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Phase 1 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Castration Resistant ◽  
Radium 223 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document